Canada's DRI Healthcare Trust Q1 total income rises

DRI Healthcare Trust

14/05/2026 22:09

Overview

Canada pharmaceutical royalty investor's Q1 total income rose to record $50.6 mln

Adjusted EBITDA for Q1 increased to $52.8 mln with margin of 90%

Company completed $250 mln senior secured notes offering and reactivated normal course issuer bid

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

MILESTONE ROYALTY RECEIPTS - Q1 included a $5 mln milestone royalty from Orserdu I related to sales performance thresholds

CAPITAL STRUCTURE ACTIONS - Issuance of $250 mln senior secured notes and refinancing of preferred securities improved financial flexibility, per CEO Ali Hedayat

Company press release: ID:nCNWd74Xwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Total Income
$50.56 mln
Q1 Adjusted Cash Earnings per Unit
$0.68
Q1 Net Income
-$984,000
Q1 Adjusted EBITDA
$52.75 mln
Q1 Adjusted EBITDA Margin
90.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dri Healthcare Trust is C$21.50, about 35.1% above its May 13 closing price of C$15.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)